AMENDMENT TO CONVERTIBLE PROMISSORY NOTEConvertible Promissory Note • December 22nd, 2023 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment to Convertible Promissory Note (this “Amendment”) is entered into as of December 21, 2023, by and between Streeterville Capital, LLC, a Utah limited liability company (“Lender”), and Outlook Therapeutics, Inc., a Delaware corporation (“Borrower”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the Note (as defined below).
